ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
ANEW MEDICAL, INC. (NASDAQ: WENA) has announced plans to develop therapeutics using novel proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain to treat weight loss and eating disorders. This approach is based on a worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona.
The company aims to target obesity and cachexia through orally administered peptide formulations, potentially offering a more affordable alternative to injectable semaglutide-based medications. Animal studies have shown promising results in weight loss and improved energy levels. This program aligns with ANEW's existing neuroscience initiatives and leverages the critical role of the central melanocortin system in regulating body weight.
ANEW MEDICAL, INC. (NASDAQ: WENA) ha annunciato piani per sviluppare terapie utilizzando peptidi proprietari innovativi che si legano selettivamente e attivano recettori melanocortinici nelle cellule neuronali del cervello per trattare la perdita di peso e i disturbi alimentari. Questo approccio si basa su un accordo di licenza mondiale con Teleost Biopharmaceuticals e l'Università dell'Arizona.
L'azienda mira a combattere l'obesità e la cachessia attraverso formulazioni di peptidi somministrate per via orale, offrendo potenzialmente un'alternativa più accessibile ai farmaci a base di semaglutide iniettabile. Gli studi sugli animali hanno mostrato risultati promettenti nella perdita di peso e nel miglioramento dei livelli di energia. Questo programma si allinea con le attuali iniziative nel settore neuroscientifico di ANEW e sfrutta il ruolo cruciale del sistema melanocortinico centrale nella regolazione del peso corporeo.
ANEW MEDICAL, INC. (NASDAQ: WENA) ha anunciado planes para desarrollar terapias utilizando péptidos innovadores y patentados que se unen selectivamente y activan receptores melanocortínicos en las células neuronales del cerebro para tratar la pérdida de peso y los trastornos alimentarios. Este enfoque se basa en un acuerdo de licencia mundial con Teleost Biopharmaceuticals y la Universidad de Arizona.
La empresa tiene como objetivo abordar la obesidad y la caquexia mediante formulaciones de péptidos administradas por vía oral, ofreciendo potencialmente una alternativa más asequible a los medicamentos inyectables a base de semaglutida. Los estudios en animales han mostrado resultados prometedores en la pérdida de peso y la mejora de los niveles de energía. Este programa se alinea con las iniciativas existentes en neurociencia de ANEW y aprovecha el papel crítico del sistema melanocortínico central en la regulación del peso corporal.
ANEW MEDICAL, INC. (NASDAQ: WENA)는 체중 감소 및 식이 장애를 치료하기 위해 뇌의 신경 세포에서 멜라노코르틴 수용체에 선택적으로 결합하고 활성화하는 새로운 독점 펩타이드 치료제를 개발할 계획을 발표했습니다. 이 접근은 Teleost Biopharmaceuticals 및 애리조나 대학과의 세계적인 라이센스 계약을 기반으로 합니다.
회사는 경구 투여되는 펩타이드 제형을 통해 비만 및 악액질을 목표로 하여, 주사형 세마글루타이드 약물에 대한 보다 저렴한 대안을 제공할 가능성이 있습니다. 동물 연구에서는 체중 감소 및 에너지 수준 향상에 대한 유망한 결과가 나타났습니다. 이 프로그램은 ANEW의 기존 신경과학 이니셔티브와 일치하며, 체중 조절에 있어 중앙 멜라노코르틴 시스템의 중요한 역할을 활용합니다.
ANEW MEDICAL, INC. (NASDAQ: WENA) a annoncé des plans pour développer des thérapeutiques utilisant de nouveaux peptides propriétaires qui se lient sélectivement et activent les récepteurs mélanocortiniques dans les cellules neuronales du cerveau afin de traiter la perte de poids et les troubles alimentaires. Cette approche repose sur un accord de licence mondial avec Teleost Biopharmaceuticals et l'Université de l'Arizona.
La société vise à cibler l'obésité et la cachexie grâce à des formulations de peptides administrées par voie orale, offrant potentiellement une alternative plus abordable aux médicaments injectables à base de sémaglutide. Des études animales ont montré des résultats prometteurs en termes de perte de poids et d'amélioration des niveaux d'énergie. Ce programme s'aligne avec les initiatives existantes en neurosciences d'ANEW et exploite le rôle crucial du système mélanocortinique central dans la régulation du poids corporel.
ANEW MEDICAL, INC. (NASDAQ: WENA) hat Pläne angekündigt, Therapeutika zu entwickeln, die neuartige proprietäre Peptide verwenden, die selektiv an Melanocortin-Rezeptoren in neuronalen Zellen im Gehirn binden und diese aktivieren, um Gewichtsverlust und Essstörungen zu behandeln. Dieser Ansatz basiert auf einer weltweiten Lizenzvereinbarung mit Teleost Biopharmaceuticals und der Universität von Arizona.
Das Unternehmen zielt darauf ab, Fettleibigkeit und Kachexie durch oral verabreichte Peptidformulierungen zu bekämpfen, die möglicherweise eine kostengünstigere Alternative zu injizierbaren Medikamenten auf Semaglutid-Basis bieten. Tierstudien haben vielversprechende Ergebnisse beim Gewichtsverlust und bei der Verbesserung der Energielevel gezeigt. Dieses Programm entspricht den bestehenden neuro-wissenschaftlichen Initiativen von ANEW und nutzt die entscheidende Rolle des zentralen Melanocortin-Systems bei der Regulierung des Körpergewichts.
- Worldwide licensing agreement secured for novel peptide-based therapeutics
- Potential for orally administered weight loss medications
- Targeting both obesity and cachexia (anorexia or sarcopenia)
- Promising results from animal studies showing weight loss and improved energy levels
- Potential for more affordable treatment compared to existing semaglutide-based medications
- None.
Insights
ANEW MEDICAL's focus on melanocortin receptor binding peptides for treating weight loss and eating disorders represents a promising neurological approach. Unlike GLP-1 agonists like semaglutide, which primarily target the digestive system, this approach directly engages the brain's central melanocortin system. This system is crucial for regulating body weight and energy homeostasis.
The potential for oral administration is a significant advantage, potentially improving patient compliance and reducing costs compared to injectable treatments. However, it's important to note that while animal studies show promise, human trials will be necessary to confirm efficacy and safety. The ability to target both obesity and cachexia suggests versatility, but each condition may require different activation patterns of melanocortin receptors.
Overall, this approach could offer a more targeted and potentially safer alternative to current weight loss medications, but extensive clinical research will be required to validate these hypotheses.
ANEW MEDICAL's entry into the weight loss and eating disorders market is strategically sound, given the global obesity epidemic and the recent success of GLP-1 agonists. The weight loss market, as demonstrated by Novo Nordisk and Eli Lilly, has immense potential, with semaglutide-based drugs becoming blockbusters.
The company's approach offers several potential advantages:
- Oral administration, which could expand the addressable market
- Potentially lower production costs, leading to more affordable treatments
- A novel mechanism of action that could differentiate it from existing therapies
However, ANEW MEDICAL faces significant challenges, including:
- High development costs and regulatory hurdles
- Strong competition from established players
- The need for extensive clinical trials to prove efficacy and safety
While the potential is substantial, investors should be aware that drug development is a long and risky process, especially for a smaller company like ANEW MEDICAL.
- Melanocortin receptors on neurons in the brain control feeding and weight loss
- Patented peptide molecules delivered orally as a pill can control feeding disorders and weight loss
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA) has announced that, as a result of its worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona, it plans to pursue the development of therapeutics using novel proprietary peptides that selectively bind and activate melanocortin receptors on neuronal cells in the brain. The neurobiology of overeating and obesity is well known, and the melanocortin-3 and melanocortin-4 receptors are definitively involved in the control of eating disorders and obesity.
Data from the World Health Organization (WHO) indicate that the state of being overweight and obese constitutes the fifth leading risk for death globally. At least 2.8 million adults die each year as a result of being overweight. In addition,
Dr. Joseph Sinkule, Founder and CEO of ANEW, commented: "Through our agreements with Teleost and the University of Arizona, we have licensed patents and know-how to develop pharmaceutical products for weight loss and eating disorders. This program fits in well with our other neuroscience programs and we believe this program is quite compelling. The eating disorders we plan to target will include obesity (overeating) but also cachexia (anorexia or sarcopenia). Studies in animal models of obesity show that we can administer the peptide formulations by mouth (orally) instead of by injection (e.g. the semaglutides) and the authors of those studies have observed weight loss and improved energy levels. Small peptides can be synthesized and administered orally, which we expect to enable these medications to be significantly more affordable than the retail cost of the semaglutides.”
The central melanocortin system in the brain plays a critical role in regulation of body weight. Melanocortins are bioactive peptides derived from a common pre-hormone produced in the brain’s hypothalamic region called “POMC” that is converted to α-melanocyte stimulating hormone (α-MSH), a major regulator in the brain of feeding and weight loss. Numerous studies have demonstrated that the hypothalamic melanocortin system is critical for the maintenance of body weight and energy homeostasis.
About ANEW MEDICAL, INC.:
ANEW MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS). The Company has obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting-edge peptide, protein, gene and cell therapies to treat age-related pathologies such as Alzheimer’s and Parkinson’s Disease, ALS, multiple sclerosis and rare neurodegenerative diseases. The Company is also pursuing other programs and product candidates in the general area of neurosciences. ANEW Medical is managed by a team of individuals and advisors that are highly experienced in biopharmaceutical product development and commercialization.
For more information, contact:
Investor Relations
Eric Boyd
Email: IR@anewmeds.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
FAQ
What is ANEW MEDICAL's new approach to treating weight loss and eating disorders?
How does ANEW MEDICAL's (WENA) approach differ from existing weight loss medications?
What eating disorders does ANEW MEDICAL (WENA) plan to target with its new therapeutics?
What results have been observed in animal studies of ANEW MEDICAL's (WENA) weight loss peptides?
